My career in the world of investing began at an early age, fueled by the potential for profits, I first began investing at the age of 11 with the help of my father. I first began picking stocks by looking at what was going to logically make money, and I had great success. Nowadays, I specialize in quantitative and fundamental analysis for stocks, particularly in small to mid-cap stocks. I adopt a value-investing strategy with one of my key tenets being to never overpay for a stock, this mitigates risk by avoiding over-priced equities that have the potential for big losses. I typically hold stocks until either their growth prospects diminish or their price-to-earnings ratio justifies a sale. My motivation for writing on Seeking Alpha stems from a desire to share my insights and analyses with a broader audience, hoping they can benefit as well. Through my articles, I aim to provide valuable perspectives and build a community of like-minded investors who can benefit from each other’s knowledge.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
#CorMedix #Strong #Adoption #Curve #Policy #Environment #NASDAQCRMD